Princeton Global Asset Management LLC Purchases 400 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Princeton Global Asset Management LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 400.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 500 shares of the biopharmaceutical company’s stock after acquiring an additional 400 shares during the quarter. Princeton Global Asset Management LLC’s holdings in Gilead Sciences were worth $46,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares in the last quarter. nVerses Capital LLC purchased a new position in Gilead Sciences in the third quarter valued at about $25,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences in the fourth quarter valued at about $29,000. Valued Wealth Advisors LLC grew its stake in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. Finally, Crews Bank & Trust purchased a new position in Gilead Sciences in the fourth quarter valued at about $31,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Up 1.2 %

Shares of NASDAQ:GILD opened at $98.38 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $99.45. The company has a market capitalization of $122.61 billion, a PE ratio of 1,093.11, a PEG ratio of 1.37 and a beta of 0.18. The business has a 50 day moving average of $92.42 and a two-hundred day moving average of $85.96. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the previous year, the company posted $2.29 earnings per share. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.34 EPS for the current year.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at $815,198.80. This represents a 43.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 598,414 shares of company stock valued at $55,953,200 in the last three months. 0.29% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on GILD shares. Robert W. Baird lifted their target price on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Citigroup started coverage on Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price on the stock. BMO Capital Markets lifted their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, Oppenheimer boosted their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.